AWMSG medicines decisions
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG) in January 2015: leuprorelin acetate as neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer; umeclidinium (Incruse) and olodaterol (Striverdi Respimat) to relieve symptoms in chronic obstructive pulmonary disease; ponatinib to treat chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia, or to treat Philadelphia chromosome positive acute lymphoblastic leukaemia; subcutaneous rituximab to treat adults with non-Hodgkin’s lymphoma (NHL), CD20-positive diffuse large B cell NHL and stage III-IV follicular lymphoma, and as maintenance therapy for follicular lymphoma in patients who responded to induction therapy — provided the approved patient access scheme is used. See the AWMSG website for full details of restrictions.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20067592
Recommended from Pharmaceutical Press